SteelPeak Wealth LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 12.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 299,943 shares of the biopharmaceutical company’s stock after selling 44,123 shares during the period. SteelPeak Wealth LLC’s holdings in Pfizer were worth $8,422,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in PFE. Independent Financial Group LLC bought a new stake in Pfizer during the 1st quarter valued at $1,802,000. Enterprise Financial Services Corp grew its stake in shares of Pfizer by 1.6% in the first quarter. Enterprise Financial Services Corp now owns 25,681 shares of the biopharmaceutical company’s stock worth $721,000 after purchasing an additional 408 shares in the last quarter. Frazier Financial Advisors LLC increased its holdings in shares of Pfizer by 182.1% during the first quarter. Frazier Financial Advisors LLC now owns 2,559 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 1,652 shares during the period. BCGM Wealth Management LLC increased its holdings in shares of Pfizer by 10.5% during the first quarter. BCGM Wealth Management LLC now owns 54,398 shares of the biopharmaceutical company’s stock valued at $1,527,000 after purchasing an additional 5,180 shares during the period. Finally, Delta Financial Advisors LLC raised its stake in shares of Pfizer by 1.6% during the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after purchasing an additional 398 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Stock Performance
NYSE:PFE opened at $25.13 on Friday. The company has a 50-day moving average of $25.22 and a 200-day moving average of $26.18. The firm has a market cap of $143.24 billion, a price-to-earnings ratio of 19.19 and a beta of 0.35. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75.
Pfizer Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s dividend payout ratio is currently 131.30%.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on PFE. CICC Research initiated coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price for the company. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Monday, July 6th. Morgan Stanley upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Bank of America lowered their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Finally, Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $28.50.
Check Out Our Latest Analysis on PFE
More Pfizer News
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer received FDA approval for a Padcev plus Keytruda regimen in muscle-invasive bladder cancer, expanding use of the combination as a new treatment option and supporting the company’s oncology growth story. Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen
- Positive Sentiment: Analyst commentary remains constructive on Pfizer’s valuation, with some recent coverage suggesting the stock may still offer upside versus Wall Street targets despite recent weakness. Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?
- Neutral Sentiment: Market commentary also says Pfizer’s shares are below key moving averages, reflecting a cautious technical setup as investors weigh fading COVID revenue against pipeline growth, acquisitions, and dividend support. Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?
- Neutral Sentiment: Pfizer also faces a new patent dispute, as Arbutus Biopharma filed international lawsuits over lipid nanoparticle technology used in mRNA COVID-19 vaccines. The case adds legal overhang, though the financial impact is still uncertain. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
- Negative Sentiment: Pfizer suspended sales of Premarin vaginal cream in India due to supply challenges, which could weigh on near-term international product sales and signals execution issues in the supply chain. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
Pfizer Company Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Articles
- Five stocks we like better than Pfizer
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
